Actively Recruiting

Age: 40Years - 75Years
All Genders
Healthy Volunteers
NCT06139042

Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers

Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-02-10

1608

Participants Needed

1

Research Sites

113 weeks

Total Duration

On this page

Sponsors

S

Second Affiliated Hospital, School of Medicine, Zhejiang University

Lead Sponsor

G

Guangzhou Burning Rock Dx Co., Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

LIBRARY is a prospective, multi-center, observational study aimed at detecting early liver, biliary tract, and pancreatic cancers by combining assays of cell-free DNA (cfDNA) methylation, serum protein, and microRNA.

CONDITIONS

Official Title

Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers

Who Can Participate

Age: 40Years - 75Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 40 to 75 years at the time of consenting to the study
  • Able to provide written informed consent
  • Pathologically confirmed liver, biliary tract, or pancreatic cancer with no prior or ongoing anti-cancer therapy before study blood draw (Cancer Arm)
  • Confirmed diagnosis of benign liver, biliary tract, or pancreatic diseases with no prior radical treatment before blood draw (Benign Arm)
  • Able to provide sufficient and qualified blood samples (Healthy Arm)
  • No cancer-related symptoms within 30 days prior to study screening (Healthy Arm)
  • Cancer history with completed curative treatment over 3 years without recurrence (Healthy Arm)
Not Eligible

You will not qualify if you...

  • Pregnant or lactating women
  • Recipients of organ transplant or prior non-autologous bone marrow or stem cell transplant
  • Received blood transfusion within 7 days prior to study blood draw (Cancer and Benign Arms)
  • Received any anti-cancer therapy within 30 days prior to study blood draw due to diseases other than cancers (Cancer and Benign Arms)
  • Have other known malignant tumors or multiple primary tumors (Cancer Arm)
  • Confirmed diagnosis of malignancies or precancerous lesions or history of malignant tumors (Benign Arm)
  • Insufficient qualified blood samples for study tests (Healthy Arm)
  • Received blood transfusion within 30 days prior to study blood draw (Healthy Arm)
  • Received anti-infectious therapy within 14 days prior to study blood draw (Healthy Arm)
  • Received or undergoing curative cancer treatment within 3 years prior to screening (Healthy Arm)
  • Have autoimmune or other diseases with severe comorbidities (Healthy Arm)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The Second Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310009

Actively Recruiting

Loading map...

Research Team

Y

Yuan Ding, Phd

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here